Nawaf M Alotaibi1, Nadia Noormohamed1, David J Cote2, Salman Alharthi1, Joanne Doucette1, Hasan A Zaidi3, Rania A Mekary4, Timothy R Smith3. 1. Department of Pharmaceutical Business and Administrative Sciences, MCPHS University, Boston, Massachusetts, USA. 2. Computational Neurosciences Outcomes Center, Brigham and Women's Hospital Department of Neurosurgery, Harvard Medical School, Boston, USA. Electronic address: david_cote@hms.harvard.edu. 3. Computational Neurosciences Outcomes Center, Brigham and Women's Hospital Department of Neurosurgery, Harvard Medical School, Boston, USA. 4. Computational Neurosciences Outcomes Center, Brigham and Women's Hospital Department of Neurosurgery, Harvard Medical School, Boston, USA; Department of Pharmaceutical Business and Administrative Sciences, MCPHS University, Boston, Massachusetts, USA.
Abstract
OBJECTIVE: A systematic review and meta-analysis were conducted to examine the effect of growth hormone-replacement therapy (GHRT) on the recurrence of craniopharyngioma in children. METHODS: PubMed, Embase, and Cochrane databases were searched through April 2017 for studies that evaluated the effect of GHRT on the recurrence of pediatric craniopharyngioma. Pooled effect estimates were calculated with fixed- and random-effects models. RESULTS: Ten studies (n = 3487 patients) met all inclusion criteria, including 2 retrospective cohorts and 8 case series. Overall, 3436 pediatric patients were treated with GHRT after surgery and 51 were not. Using the fixed effect model, we found that the overall craniopharyngioma recurrence rate was lower among children who were treated by GHRT (10.9%; 95% confidence interval 9.80%-12.1%; I2 = 89.1%; P for heterogeneity <0.01; n = 10 groups) compared with those who were not (35.2%; 95% confidence interval 23.1%-49.6%; I2 = 61.7%; P for heterogeneity = 0.11; n = 3); the P value comparing the 2 groups was <0.01. Among patients who were treated with GHRT, subgroup analysis revealed that there was a greater prevalence of craniopharyngioma recurrence among studies conducted outside the United States (P < 0.01), single-center studies (P < 0.01), lower impact factor studies (P = 0.03), or studies with a lower quality rating (P = 0.01). Using the random-effects model, we found that the results were not materially different except for when stratifying by GHRT, impact factor, or study quality; this led to nonsignificant differences. Both Begg's rank correlation test (P = 0.7) and Egger's linear regression test (P = 0.06) indicated no publication bias. CONCLUSIONS: This meta-analysis demonstrated a lower recurrence rate of craniopharyngioma among children treated with GHRT than those who were not.
OBJECTIVE: A systematic review and meta-analysis were conducted to examine the effect of growth hormone-replacement therapy (GHRT) on the recurrence of craniopharyngioma in children. METHODS: PubMed, Embase, and Cochrane databases were searched through April 2017 for studies that evaluated the effect of GHRT on the recurrence of pediatric craniopharyngioma. Pooled effect estimates were calculated with fixed- and random-effects models. RESULTS: Ten studies (n = 3487 patients) met all inclusion criteria, including 2 retrospective cohorts and 8 case series. Overall, 3436 pediatric patients were treated with GHRT after surgery and 51 were not. Using the fixed effect model, we found that the overall craniopharyngioma recurrence rate was lower among children who were treated by GHRT (10.9%; 95% confidence interval 9.80%-12.1%; I2 = 89.1%; P for heterogeneity <0.01; n = 10 groups) compared with those who were not (35.2%; 95% confidence interval 23.1%-49.6%; I2 = 61.7%; P for heterogeneity = 0.11; n = 3); the P value comparing the 2 groups was <0.01. Among patients who were treated with GHRT, subgroup analysis revealed that there was a greater prevalence of craniopharyngioma recurrence among studies conducted outside the United States (P < 0.01), single-center studies (P < 0.01), lower impact factor studies (P = 0.03), or studies with a lower quality rating (P = 0.01). Using the random-effects model, we found that the results were not materially different except for when stratifying by GHRT, impact factor, or study quality; this led to nonsignificant differences. Both Begg's rank correlation test (P = 0.7) and Egger's linear regression test (P = 0.06) indicated no publication bias. CONCLUSIONS: This meta-analysis demonstrated a lower recurrence rate of craniopharyngioma among children treated with GHRT than those who were not.
Authors: S Mackenzie; T Craven; H R Gattamaneni; R Swindell; S M Shalet; G Brabant Journal: J Clin Endocrinol Metab Date: 2011-06-29 Impact factor: 5.958
Authors: Andrea Poretti; Michael A Grotzer; Karin Ribi; Eugen Schönle; Eugen Boltshauser Journal: Dev Med Child Neurol Date: 2004-04 Impact factor: 5.449
Authors: Sergey Gorelyshev; Alexander N Savateev; Nadezhda Mazerkina; Olga Medvedeva; Alexander N Konovalov Journal: Adv Tech Stand Neurosurg Date: 2022
Authors: Margaret C S Boguszewski; Adriane A Cardoso-Demartini; Cesar Luiz Boguszewski; Wassim Chemaitilly; Claire E Higham; Gudmundur Johannsson; Kevin C J Yuen Journal: Pituitary Date: 2021-07-25 Impact factor: 4.107